Glioblastoma Clinical Trials in Chicago, IL

View the best 10 glioblastoma medical studies in Chicago, Illinois. Access promising new therapies by applying to a Chicago-based Glioblastoma clinical trial.

Trials in Chicago, Illinois

Here are the top 10 medical studies for glioblastoma in Chicago, Illinois

Temozolomide +1 More

Alkylating agents

Recruiting1 awardPhase 1

"This trial is testing the safety and effectiveness of using a drug called triapine alongside temozolomide to treat patients with recurrent glioblastoma. Triapine stops an enzyme that helps

Atezolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 2

This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.

WP1066 +1 More

STAT3 Inhibitor

Recruiting1 awardPhase 2

This trial tests a drug/radiation combo to treat glioblastoma, a hard-to-treat brain tumor. The drug targets a specific pathway to stop growth, and radiation prevents the tumor from growing. This may extend survival.

APX005M

Monoclonal Antibodies

Recruiting1 awardPhase 1

This trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor.

IGV-001 +2 More

Cell Immunotherapy

Recruiting0 awardsPhase 2

This trial will compare a new treatment for glioblastoma to placebo to see if it extends survival.

Intraoperative radiotherapy

Recruiting2 awardsPhase 3

This trial is testing if adding intraoperative radiotherapy (IORT) to standard radiochemotherapy can improve the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM).

Triamcinolone Acetonide

Recruiting1 awardPhase 2

This trial will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects for people being treated with Tumor Treating Fields for malignant glioma.

LP-184

Recruiting1 awardPhase 1 & 2

This trial will measure how safe and tolerable a drug is and test its effectiveness in treating advanced solid tumors.

ST101

Virus Therapy

Recruiting1 awardPhase 1 & 2

This trial tests a new drug, ST101, given to patients with advanced cancers who haven't responded to other treatments. The study aims to find the safest and most effective dose. It includes patients with specific types of breast cancer, melanoma, brain cancer, and prostate cancer.

Lomustine +2 More

Alkylating agents

Recruiting2 awardsPhase 3

This trial is comparing the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in treating newly diagnosed MGMT methylated glioblastoma.

Popular Filters

Trials With No Placebo

Alkylating agents

Triapine + Temozolomide for Brain Tumors

Recruiting1 awardPhase 1

Chicago, Illinois

"This trial is testing the safety and effectiveness of using a drug called triapine alongside temozolomide to treat patients with recurrent glioblastoma. Triapine stops an enzyme that helps

Cancer Vaccine

L19TNF + Lomustine for Glioblastoma

Recruiting1 awardPhase 2

Chicago, Illinois

"This trial is studying how safe and effective the combination of L19TNF and lomustine is at different doses in patients with Glioblastoma that has progressed or come back."

ALK Inhibitor

Lorlatinib for Brain Tumors

Recruiting1 awardPhase < 1

Chicago, Illinois

This trial aims to see how well the drug loratinib works in treating children with a specific type of brain tumor called high-grade glioma. The study will also look at the safety of using lor

Alkylating agent

Olutasidenib + Temozolomide for Brain Tumors

Recruiting1 awardPhase 2

Chicago, Illinois

This trial will test if a drug can extend the life of kids/young adults with a deadly brain tumor linked to a genetic mutation.

LP-184 for Solid Tumors

Recruiting1 awardPhase 1 & 2

Rolling Meadows, Illinois

This trial will measure how safe and tolerable a drug is and test its effectiveness in treating advanced solid tumors.

Chemotherapy

Ultrasound-Assisted Chemotherapy for Glioblastoma

Recruiting2 awardsPhase 3

Chicago, Illinois

This trial tests a new method to treat recurrent brain cancer using an ultrasound device called SonoCloud-9. The device helps open the brain's protective barrier so that more of the chemotherapy drug carboplatin can reach the tumor. The goal is to see if this combination makes the treatment more effective. Carboplatin has been used in various studies for treating high-grade gliomas and glioblastomas, often showing modest efficacy due to low tissue concentration when delivered intravenously.

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.